CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL
Status:
Withdrawn
Trial end date:
2010-04-05
Target enrollment:
Participant gender:
Summary
This study is designed to test whether CT-2103/carboplatin provides improved overall survival
compared to paclitaxel/carboplatin in women with NSCLC who have estradiol levels >30 pg/ml.